Literature DB >> 32589961

SnapShot: Jak-STAT Signaling II.

Alejandro V Villarino1, Massimo Gadina1, John J O'Shea1, Yuka Kanno1.   

Abstract

The JAK-STAT pathway is an evolutionarily conserved signal transduction paradigm, providing mechanisms for rapid receptor-to-nucleus communication and transcription control. Discoveries in this field provided insights into primary immunodeficiencies, inherited autoimmune and autoinflammatory diseases, and hematologic and oncologic disorders, giving rise to a new class of drugs, JAK inhibitors (or Jakinibs). Published by Elsevier Inc.

Entities:  

Year:  2020        PMID： 32589961     DOI： 10.1016/j.cell.2020.04.052

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  12 in total

Review 1.  Recent research on the association between signal transducer and activator of transcription 5 and childhood acute lymphoblastic leukemia.

Authors:  Yi-Fei Duan; Fei-Qiu Wen
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-08-15

Review 2.  JAK inhibition as a new treatment strategy for patients with COVID-19.

Authors:  Jin Huang; Chi Zhou; Jinniu Deng; Jianfeng Zhou
Journal:  Biochem Pharmacol       Date:  2022-07-03       Impact factor: 6.100

Review 3.  JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition.

Authors:  Yiming Luo; Madison Alexander; Massimo Gadina; John J O'Shea; Francoise Meylan; Daniella M Schwartz
Journal:  J Allergy Clin Immunol       Date:  2021-10       Impact factor: 14.290

Review 4.  Small molecule inhibitors targeting the cancers.

Authors:  Gui-Hong Liu; Tao Chen; Xin Zhang; Xue-Lei Ma; Hua-Shan Shi
Journal:  MedComm (2020)       Date:  2022-10-13

Review 5.  Atopic dermatitis: an expanding therapeutic pipeline for a complex disease.

Authors:  Thomas Bieber
Journal:  Nat Rev Drug Discov       Date:  2021-08-20       Impact factor: 84.694

6.  JAK/STAT inhibitor therapy partially rescues the lipodystrophic autoimmune phenotype in Clec16a KO mice.

Authors:  Rahul Pandey; Marina Bakay; Bryan P Strenkowski; Heather S Hain; Hakon Hakonarson
Journal:  Sci Rep       Date:  2021-04-01       Impact factor: 4.379

7.  Inhibition of CUB and sushi multiple domains 1 (CSMD1) expression by miRNA-190a-3p enhances hypertrophic scar-derived fibroblast migration in vitro.

Authors:  Shuchen Gu; Xin Huang; Xiangwen Xu; Yunhan Liu; Yimin Khoong; Zewei Zhang; Haizhou Li; Yashan Gao; Tao Zan
Journal:  BMC Genomics       Date:  2021-08-12       Impact factor: 3.969

Review 8.  miRNAs as Biomarkers and Possible Therapeutic Strategies in Rheumatoid Arthritis.

Authors:  Tomasz Kmiołek; Agnieszka Paradowska-Gorycka
Journal:  Cells       Date:  2022-01-28       Impact factor: 6.600

9.  Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms.

Authors:  Mengshi Hu; Tao Yang; Linyu Yang; Lu Niu; Jinbing Zhu; Ailin Zhao; Mingsong Shi; Xue Yuan; Minghai Tang; Jianhong Yang; Heying Pei; Zhuang Yang; Qiang Chen; Haoyu Ye; Ting Niu; Lijuan Chen
Journal:  Blood Cancer J       Date:  2022-03-07       Impact factor: 11.037

Review 10.  Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies.

Authors:  Madison Alexander; Yiming Luo; Giorgio Raimondi; John J O'Shea; Massimo Gadina
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.